BIOSECURE and Beyond: What it Really Means for Pharma Supply Chains

The US pharmaceutical industry is entering a new phase of supply chain transformation. Regulatory pressure, geopolitical uncertainty, new patient populations, and innovative modalities are forcing companies to rethink not only where medicines are produced, but how they move across an increasingly complex global landscape.

At the center of this shift is the BIOSECURE Act. This act is designed to restrict the use of certain foreign biotechnology providers within US supply chains, but the net effect is the move away from reliance on overseas suppliers, in particular, less dependence on long-haul Asia lanes. This means pharmaceutical companies are reassessing long-established manufacturing partnerships, shifting production footprints and building new supplier networks that align with evolving regulatory expectations.

While these changes are often framed as a way to reduce risk, they are also introducing new layers of complexity. As supply chains become more distributed, they become harder to manage.

As networks expand, ensuring that temperature-sensitive medicines reach patients safely and on time is becoming more challenging and more critical.

How Is BIOSECURE Reshaping Pharmaceutical Supply Chains?

The impact of BIOSECURE is not limited to compliance. It is driving structural change across pharmaceutical supply chains, particularly in how companies source materials and manufacture products.

In response, many organizations are turning to near-shoring and friend-shoring strategies, moving production closer to key markets or towards regions seen as more stable and transparent. At the same time, reliance on a single supplier or geography is being replaced by more diversified networks. This reduces exposure to disruption, but it also creates supply chains that are inherently more complex, with multiple production sites, partners and transport routes to manage.

For temperature-sensitive medicines, including vaccines, biologics and advanced therapies, this shift has significant implications. Each additional node in the supply chain introduces another point where conditions must be tightly controlled. What was once a relatively straightforward journey is now a multi-stage process where consistency and reliability become harder to maintain.

How New supply Routes Bring New Cold Chain Challenges

As the number of touchpoints in a supply chain rises, so too does the risk of delays, handling inconsistencies and temperature deviations. Each transfer between partners or modes of transport creates a moment where product integrity could be compromised, particularly if processes and standards are not fully aligned.

Meanwhile, regulatory expectations are becoming more stringent. Frameworks such as the FDA’s Drug Supply Chain Security Act and global GDP (Good Distribution Practice) guidelines are placing greater emphasis on traceability, data integrity and proof that products have remained within required temperature ranges throughout their journey. For pharmaceutical companies, this means not only managing the physical movement of goods but also maintaining robust, auditable data across the entire supply chain.

The stakes are even higher for newer, more complex therapies. Cell-based treatments and some gene-modified cell therapies are highly sensitive biological products that require extremely low temperatures. These therapies often need cryogenic storage below -150 °C, and in some cases as low as -196 °C. Many gene therapies, such as AAV-based products, are stored and transported at ultra-low temperatures around -70 °C to -80 °C. In all cases, temperature excursions outside validated limits can affect product viability or potency, making precise temperature control essential from manufacturing through to administration.

External pressures add further uncertainty. As we’ve seen in recent months, climate variability, differences in infrastructure between regions and ongoing geopolitical disruption can all impact transport reliability. Routes that were once predictable may no longer offer the same level of stability, increasing the need for supply chains that can adapt quickly without compromising quality.

Building Resilience Into the Next Generation of Cold Chains

In this environment, resilience is no longer a nice-to-have; it is fundamental. Pharmaceutical companies need supply chains that can respond to changing routes, partners and conditions while maintaining strict control over product quality.

This starts with the physical infrastructure used to transport medicines. Container solutions must be able to perform consistently across different climates, handling conditions and transport modes, reducing the risk of temperature excursions even as supply chains become more dynamic. The ability to rely on consistent performance, regardless of route, is critical when there is no room for error.

At the same time, greater connectivity is changing how cold chains are managed. Real-time monitoring technologies allow logistics teams to track shipments continuously, identify potential issues early and take corrective action before product integrity is affected. This shift towards more proactive management is key in a landscape where delays and disruptions are harder to predict.

Equally important is the strength of the supporting network. As manufacturing moves into new locations, access to a global infrastructure of service stations, partners and expertise becomes essential. This enables pharmaceutical companies to scale and adapt their supply chains without introducing additional risk, ensuring that new routes can be supported to the same standard as established ones.

And finally, underpinning all of this is the need for closer collaboration. Manufacturers, logistics providers and technology partners need to work together to align processes, share data and respond effectively to disruption. In a more distributed supply chain environment, coordination is critical to maintaining consistent quality from start to finish.

Keeping Patients at the Center

As US pharmaceutical supply chains evolve under the combined weight of regulation and geopolitics, the cold chain is becoming a central pillar of success. Making sure that medicines move safely across shifting trade lanes requires flexibility, robust infrastructure and the ability to act quickly when conditions change.

For companies navigating the post-BIOSECURE landscape, the question is no longer just where products are made. It is whether they can be delivered reliably, without compromise, to the patients who depend on them.

In an increasingly complex supply chain environment, protecting product integrity is essential. Ultimately, it is what safeguards patient outcomes and maintains trust in the therapies being delivered.

Barbara Morgan is the regional president of the Americas at Envirotainer.